drugset / Trial / NCT00871182

Study to Evaluate the Safety and Efficacy of Inhaled PT001 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00871182

Phase 1/2 Completed 33 enrolled Pearl Therapeutics, Inc.
RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of inhaled PT001 compared to placebo and tiotropium in patients with mild to moderate chronic obstructive pulmonary disease (COPD).

Timeline

Start
2009-03
Primary completion
2009-09
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Glycopyrrolate Small molecule 18 ug Inhaled
Subject Glycopyrrolate Small molecule 36 ug Inhaled
Subject Glycopyrrolate Small molecule 72 ug Inhaled
Subject Glycopyrrolate Small molecule 144 ug Inhaled
Comparator Tiotropium Other / unclassified 18 ug